EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients

Sara Merdita, Pavel Ryšánek, Jan Miroslav Hartinger, Ondřej Slanař, Martin Šíma

Prague Medical Report · 2024

DOI: 10.14712/23362936.2024.18 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Prague Medical Report, 2024. Verfasst von Sara Merdita und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. Hauptthemen laut MEDLINE: Mycophenolic Acid, Immunosuppressive Agents, Organ Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstvo Zdravotnictví Ceské Republiky.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycophenolate mofetil (MMF) is an immunosuppressant drug approved for prophylaxis of transplant rejection in patients undergoing solid organ transplantation and is further employed in management of various autoimmune disorders. MMF exhibits notable pharmacokinetic inter- and intraindividual variability necessitating tailored therapeutic approaches to achieve optimal therapeutic outcomes while mitigating risks of adverse effects. The objective of this review was to summarize factors that influence the pharmacokinetics of MMF and its active metabolite mycophenolic acid in order to deduce recommendations for personalized treatment strategies. Presumed predictors were analysed in relation to each of the four pharmacokinetic phases, providing tools and targets for MMF dosing optimization amenable to clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidImmunosuppressive AgentsOrgan TransplantationHumansGraft RejectionPrecision Medicine

Stichwörter der Autor:innen

ImmunosuppressantsMycophenolate mofetilMycophenolic acidPersonalized medicinePharmacokineticsTherapeutic drug monitoring

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
  • Institute of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic. martin.sima@lf1.cuni.cz.

Förderung

  • Ministerstvo Zdravotnictví Ceské Republiky

Zitieren

APA

Merdita, S., Ryšánek, P., Hartinger, J. M., Slanař, O., & Šíma, M. (2024). Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients. Prague Medical Report. https://doi.org/10.14712/23362936.2024.18

Vancouver

Merdita S, Ryšánek P, Hartinger JM, Slanař O, Šíma M. Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients. Prague Medical Report. 2024. doi:10.14712/23362936.2024.18

BibTeX
@article{Merdita2024,
  author = {Merdita, Sara and Ryšánek, Pavel and Hartinger, Jan Miroslav and Slanař, Ondřej and Šíma, Martin},
  title = {Pharmacokinetic-based Dosing Individualization of Mycophenolate Mofetil in Solid Organ Transplanted Patients},
  journal = {Prague Medical Report},
  year = {2024},
  doi = {10.14712/23362936.2024.18}
}
Kostenlos starten →